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Introduction:  Antiepileptic  drugs,  which  are  also  called  anticonvulsants,  are  used  in the
therapy  and  prophylaxis  of  epileptic  seizures.  The  purpose  of  this  paper  was  to  investi-
gate  the  relevant  epidemiological  data  and  to determine  which  of these  drugs  was  the
most frequent  cause  of  intoxication.  Another  purpose  of  this  study  was  to  determine  the
neurological,  cardiac,  and  biochemical  problems  caused  by antiepileptics.
Material  and method:  This  retrospective  study  included  95  consecutive  patients  under  18
years  of age  with  antiepileptic  intoxication,  presenting  to and  being  followed-up  in, the  Tox-
icology Unit  between  January  2010  and  February  2013.  The  data  were  obtained  by  screening
the  patient  ﬁles.
Results: Of  the cases,  67  (70.5%)  were  self-poisoned  by  ﬁrst generation  antiepileptics  (FGAEs)
and 28  (29.5%)  by  second  generation  antiepileptics  (SGAEs).  The  Glasgow  Coma  Scale  (GCS)
scores and the serum  lactate  levels  of  the patients  poisoned  by  FGAEs  and  SGAEs  on admis-
sion  to  emergency  department  were  15  (25th:  12;  75th:  15;  95th:  15; IQR: 3)  and 1.9
(25th:  1.4;  75th:  3.1; 95th:  5.6; IQR:  1.7),  and  15  (25th:  14.3;  75th:  15;  95th:  15; IQR:  0.75)
and  1.07  (25th:  0.9;  75th: 1.6;  95th:  5.5;  IQR: 0.71),  respectively.  The  serum  lactate  levels  of
patients  poisoned  by  FGAEs  were  signiﬁcantly  higher  (p <  0.001).  Among  the  cases  poisoned
by carbamazepine,  the  most frequent  cause  of  intoxication,  the GCS  score  was  signiﬁcantly
lower  and serum  lactate  level  was  signiﬁcantly  higher  in  the  group  with  high  serum  levels
of carbamazepine  (p =  0.004  and  p <  0.001,  respectively).  In cases  poisoned  by  valproic  acid
(VPA),  the  second  frequent  cause  of intoxication,  there  was  neither  a signiﬁcant  associa-
tion  between  the  serum  VPA  level  and  the GCS  score,  nor  between  the  serum  lactate  level
and  the  systolic  blood  pressure  (p = 0.470,  p =  0.897,  and  p =  0.088,  respectively).  However,
there  was  a positive  correlation  between  the  serum  VPA  level  and  the  serum  ammonia  level
(kk = 0.742,  p  <  0.001).
Conclusion:  First  generation  antiepileptics  are  more  toxic  than  SGAEs.  In patients  with  serum
carbamazepine  level,  particularly  those  over  30 mg/L,  serious  disorders  of  consciousness,
cardiovascular  toxicity,  and  metabolic  disorders  may  occur.  In VPA  intoxication,  there  is a
n  betwepositive  correlatio
ﬁnding,  one  should  be m
the serum  VPA  level  rises
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Table 1
Age distribution of patients.
Age group (years) Number (n) Percent (%)
18–20 44 46.3
20–30 25 26.3
30–40 15 15.8
40–50 7 7.4
50–60 2 2.1
60–70 1 1.1
frequent intoxications, in 40% (n = 38) and 27.4% (n = 26)
of the patients, respectively. The demographic data of the
patients have been summarized in Tables 1 and 2, and the
Table 2
Age and gender distribution of patients.
Gender Number (n) Median age (years)Y.K. Günaydın et al. / Tox
. Introduction
Antiepileptic drugs, which are also referred to as anti-
onvulsants, are used in the treatment and prophylaxis
f epileptic seizures. The ﬁrst antiepileptics, which were
ntroduced to clinical use in 1939, were phenytoin and phe-
obarbital. These drugs were followed by ﬁrst generation
ntiepileptics (FGAEs), such as carbamazepine and valproic
cid (VPA), and later, by second generation antiepilep-
ics (SGAEs), namely gabapentin and lamotrigine. Overdose
f FGAEs has the potential of causing serious intoxica-
ion. Due to their narrow therapeutic windows, they may
ause intoxications even at therapeutic doses. Acute tox-
city caused by these drugs can be due to unintentional
r suicidal intake, as well as to chronic use for therapy
1,2]. The purpose of this study was to assess the relevant
pidemiological data, to ﬁnd which of the antiepileptics
as the most frequent cause of intoxication, and to deter-
ine the neurological, cardiac, and biochemical problems
aused by antiepileptics. Another purpose of the study was
o assess in particular the correlation between the levels of
arbamazepine and VPA and the clinical picture in antilep-
ic intoxications, and to compare the efﬁcacies of different
herapeutic approaches.
. Material and method
.1. Study design and population
In the Toxicology Unit of our Emergency Department,
atients presenting with unintentional or suicidal poison-
ng are hospitalized and followed-up by specialists and
esident physicians of emergency medicine. This unit has
ntensive care beds for the follow-up of patients requiring
echanical ventilation. This retrospective study com-
rised 95 consecutive patients aged 18-year-old and older
ith antiepileptic intoxication, presenting to and being
ollowed-up in our Toxicology Unit between January 2010
nd February 2013. The data were obtained by reviewing
he patient ﬁles.
.2. Study protocol
The patients were evaluated in terms of gender, age, the
rugs they were exposed to or took, the serum drug levels,
he route and reason for taking the drugs (unintentional
r suicidal), the clinical picture, the therapeutic methods
pplied, complications, the length of hospitalization, and
ortality.
.3. Collection of data and statistical analysis
In this retrospective study, the data were obtained by
eviewing the patients’ ﬁles. The study included all patients
etween the ages of 18 and 80 with antiepileptic intoxica-
ion who had been hospitalized in the Toxicology Unit for
t least 24 h for examination and therapy.Statistical analysis was performed using SPSS v.15.0 for
indows. Both visual (histogram and probability graphs)
nd analytical (Kolmogorov–Smirnov and Shapiro–Wilk
ests) methods were used to determine if the data were70–80 1 1.1
Total 95 100.0
normally distributed. Descriptive variables are expressed
as mean ± SD for data that are normally distributed and
as median and interquartile range (IQR) for variables
that are not normally distributed. Clinical and laboratory
characteristics were evaluated via Mann–Whitney U test
for variables without normal distribution. Patients were
divided into three groups according to their level of drug.
Comparison of these three groups by the Kruskal–Wallis
test was used. When necessary, the Mann–Whitney U test
with the Bonferroni correction was used to compare vari-
ables. The Spearman’s rho correlation test was  performed
for correlations. A p value of <0.05 was accepted as statis-
tically signiﬁcant with 95% conﬁdence interval.
The study protocol was approved by the local ethics
committee and conducted in accordance with the Decla-
ration of Helsinki and Good Clinical Practices.
3. Results
3.1. Demographic data
The median age of the 95 patients included in the study
was 21 (25th: 19; 75th: 31; 95th: 48.6; IQR: 12) years. Of 95
patients, 24 (25.3%) were male and 71 (74.7%) were female,
with a male:female ratio of 1:3. The median age of males
was 25.5 (25th: 20; 75th: 35; 95th: 71.6; IQR: 15) years and
that of females was  20 (25th: 19; 75th: 29; 95th: 49.2; IQR:
10) years. The cause of intoxication in 91 (95.8%) patients
was taking an excessive amount of the drug for suicidal
purpose, and in 4 (4.2%), the cause was  a side-effect of the
drug used for therapy.
All of the cases were self-poisoned by the oral route.
Apart from the patients with intoxication as the side-effect
of the drugs, all patients self-poisoned for suicide admin-
istered gastric lavage and activated charcoal. Of the cases,
67 (70.5%) were poisoned with FGAEs and 28 (29.5%) with
SGAEs. Carbamazepine and VPA poisonings were the mostMale 24 (25.3%) 25.5 (25th: 20; 75th: 35; 95th: 71.6; IQR: 15)
Female 71 (74.7%) 20 (25th: 19; 75th: 29; 95th: 49.2; IQR: 10)
Total 95 (100%) 21 (25th: 19; 75th: 31; 95th: 48.6; IQR: 12)
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Table 3
Classiﬁcation of antiepileptic drugs.
Drugs Number (n) Percent (%)
First generation 67 70.5
Second generation 28 29.5
Table 4
The distribution of patients poisoned drugs.
Drugs Number (n) Percent (%)
Carbamazepine 38 40.0
Valproic acid 26 27.4
Gabapentin 10 1.5
Topiramate 5 5.3
Levetiracetam 7 7.4
Pregabalin 3 3.2
Lamotrigine 2 2.1
Fenobarbital 1 1.1
Phenytoin 1 1.1
Table 5
Patients’ characteristics.
Number (n)
Age (median) 21 (25th: 19; 75th: 31; 95th: 48.6; IQR: 12)
Glasgow Coma Score
(median)
15 (25th: 13; 75th: 15; 95th: 15; IQR: 2)
First electrocardiography
Normal sinus rhythm 74 (77.9%)
Sinus tachycardia 18 (18.9%)
Sinus bradycardia 2 (2.1%)
Left bundle branch
block
1 (1.1%)
Treatment methods
General intoxication
treatment
58 (61.1%)
Hemoperfusion 22 (23.2%)
Carnitine 7 (7.4%)
Hemoperfusion and
carnitine
6 (6.3%)
NaHCO3 2 (2.2%)
Mechanical ventilation requirements
No 90 (94.7%)
Yes 5 (5.3%)
Result
Discharged with 94 (98.9%)Clonazepam 2 2.1
Total 95 100.0
distribution of intoxicating drugs has been presented in
Tables 3 and 4.
3.2. Primary results
The median GCS score of the patients on admission to
emergency department was 15 (25th: 13; 75th: 15; 95th:
15; IQR: 2). The electrocardiograms of the patients at the
time of presentation demonstrated normal sinus rhythm in
74 (77.9%), sinus tachycardia in 18 (18.9%), sinus bradycar-
dia in 2 (2.1%), and left branch block in 1 (1.1%). As therapy,
58 (61.1%) patients received general treatment of poison-
ing and supportive therapy. Of the patients, 22 (23.2%)
patients received hemoperfusion, 7 (7.4%) received carni-
tine, 6 (6.3%) received carnitine and hemoperfusion, and
2 (2.2%) received NaHCO3. Only 5 (5.3%) patients required
mechanical ventilation, and 1 (1.1%) patient died. Of the
5 patients who underwent mechanical ventilation, 2 had
disorder of consciousness due to carbamazepine, 2 had
ammonemic hepatic encephalopathy and lactic acidosis
due to VPA, and 1 had disorder of consciousness, lactic acid-
osis, and consequently, pneumosepsis due to gabapentine
intoxication. One patient, who had a disorder of conscious-
ness and lactic acidosis caused by gabapentine intoxication
received mechanical ventilation, but died of the conse-
quently developing pneumonia and septic shock (Table 5).
The Glasgow Coma Scale (GCS) scores and the serum lac-
tate levels of the patients poisoned by FGAEs and SGAEs on
admission to emergency department were 15 (25th: 12;
Table 6
The resulting differences in terms of severity of poisoning between two generatio
First generation (n = 67)
Median (25th; 75th; 95th; IQR)
Age (years) 22 (19; 33; 49.8; 14) 
Lactate (mmol/L) 1.9 (1.4; 3.1; 5.6; 1.7) 
GKS 15 (12; 15; 15; 3) 
Length of stay in hospital (days) 3 (2; 3; 5.6; 1) 
GCS, Glasgow Coma Score.
a Mann–Whitney test.healing
Died 1 (1.1%)
75th: 15; 95th: 15; IQR: 3) and 1.9 (25th: 1.4; 75th: 3.1;
95th: 5.6; IQR: 1.7), and 15 (25th: 14.3; 75th: 15; 95th: 15;
IQR: 0.75) and 1.07 (25th: 0.9; 75th: 1.6; 95th: 5.5; IQR:
0.71), respectively. The serum lactate levels of patients poi-
soned by FGAEs were signiﬁcantly higher (p < 0.001). There
was  no signiﬁcant difference among the patient groups
poisoned by FGAEs and SGAEs in terms of age, GCS score,
and the length of hospitalization (p = 0.459, p = 0.055, and
p = 0.774, respectively) (Table 6).
3.3. Secondary results
We  assessed the cases poisoned by carbamazepine, the
most frequent cause of intoxication in our study, in terms
of association between the serum carbamazepine level and
the age, the GCS score and also between the serum lac-
tate level and the systolic blood pressure on admission
to emergency medicine. We  divided the carbamazepine
poisoning patients into 3 groups according to serum car-
bamazepine levels as follows: under 15 mg/L (Group 1,
n = 12), between 15 and 30 mg/L (Group 2, n = 13), and over
30 mg/L (Group 3, n = 13). We  observed that in the group
with high levels of carbamazepine levels, GCS score was
signiﬁcantly lower, and the serum lactate level was sig-
niﬁcantly higher (p = 0.004 and p < 0.001). When the cause
ns.
Second generation (n = 28)
Median (25th; 75th; 95th; IQR)
p
20 (19; 28; 62.9; 9.75) 0.459a
1.07 (0.9; 1.6; 5.5; 0.71) <0.001a
15 (14.3; 15; 15; 0.75) 0.055a
3 (2; 3; 4; 1) 0.774a
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Table  7
Between the serum carbamazepine level and the mean GCS and also between the serum lactate level and the systolic arterial pressure.
Serum levels of carbamazepine (mg/L) p
<15 (n = 12) 15–30 (n = 13) >30 (n = 13)
Median (25th; 75th; 95th; IQR)
Age (years) 20 (18; 23.5; 32.7; 5.5) 33 (19.5; 44; 52.2; 24.5) 24 (18.5; 35.5; 55; 17) 0.081a
Lactate (mmol/L) 1.6 (1.2; 1.9; 2.3; 0.67) 1.5 (1.3; 1.8; 2.9; 0.57) 2.8 (1.9; 3.8; 5.4; 1.9) <0.001a
GKS 15 (13.2; 15; 15; 1.75) 15 (12.5; 15; 15; 2.5) 10 (10; 13; 15; 3) 0.004a
Blood pressure (mmHg) 112.5(106.3; 120; 128; 13.7) 110 (95; 117.5; 146; 22.5) 90 (90; 124; 140; 34) 0.142a
GKS, Glasgow Coma Score; blood pressure, mean systolic blood pressure value.
a Kruskal–Wallis test.
Table 8
Between serum VPA level and the mean GCS, and also between the serum lactate level and the systolic arterial pressure.
Serum levels of valproic acid (mg/L) p
<100 (n = 7) 100–125 (n = 10) >125 (n = 9)
Median (25th; 75th; 95th; IQR)
Age (years) 20 (19; 20; 32.5; 1) 23.5(18.7; 26.5; 32.5; 7.7) 28(19; 29.5; 32.5; 10.5) 0.431a
Lactate (mmol/L) 2.95(1.4; 4.2; 6.8; 2.82) 2.03 (1.6; 4.8; 6.8; 3.21) 3.1 (2.2; 3.6; 6.8; 1.39) 0.897a
GKS 15 (13; 15; 15; 2) 15 (14.5; 15; 15; 0.5) 15 (10.5; 15; 15; 4.5) 0.470a
110 (
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GBlood pressure (mmHg) 120 (110; 130; 119; 20) 
KS, Glasgow Coma Score; blood pressure, mean systolic blood pressure 
a Kruskal–Wallis test.
f these differences was evaluated, we found a statisti-
ally signiﬁcant difference between Group 3 and Group 1
n terms of GCS score (p = 0.001). There was also a signiﬁ-
ant difference between Group 1 and Group 3, as well as,
etween Group 2 and Group 3 in terms of the serum lac-
ate level (p < 0.001 and p < 0.001, respectively). There was
o difference in terms of age and systolic blood pressure
etween the groups (p = 0.142 and p = 0.081) (Table 7). Like-
ise, there was  a signiﬁcant positive correlation between
he serum carbamazepine level and the serum lactate level,
nd a signiﬁcant negative correlation between the serum
arbamapezine level and GCS score (kk = 0.602, p < 0.001;
nd kk = −0.568, p < 0.001, respectively) (Table 9).
We assessed the cases poisoned by VPA, the second
ost frequent cause of intoxication in our series, in terms
f the association between serum VPA level and age, the
CS score, and also between the serum lactate level and
he systolic blood pressure at the time of presentation. We
ivided the VPA poisoning patients into 3 groups accord-
ng to serum VPA levels as follows: under 100 mg/L (Group
, n = 7), between 100 and 125 mg/L (Group 2, n = 10),
nd over 125 mg/L (Group 3, n = 9). There was no signif-
cant difference between the serum VPA level and GCS
core, nor between the serum VPA level and the serum
able 9
orrelations.
Serum level of valproic acid 
kk 
Age (years) 0.171 
Lactate (mmol/L) 0.132 
GKS −0.185 
Blood pressure (mmHg) −0.286 
Ammoniac (g/dl) 0.742 
KS, Glasgow Coma Score; blood pressure, mean systolic blood pressure value.
a Spearman’s rho.103.7; 110; 119; 6.25) 110 (75; 110; 119; 45) 0.088a
lactate level and the systolic blood pressure (p = 0.470,
p = 0.897, p = 0.088, respectively) (Table 8). Likewise, there
was no signiﬁcant correlation between the serum VPA
level and the serum lactate level, nor between the serum
VPA level and the GCS score, the systolic blood pres-
sure, and age (kk = 0.132, p = 0.520; kk = −0.185, p = 0.130,
kk = −0.286, p = 0.156, kk = 0.171, p = 0.404, respectively)
(Table 9). However, there was  a signiﬁcant positive correla-
tion between the serum VPA level and the serum ammonia
level (kk = 0.742, p < 0.001).
3.4. Study limitations
The most important limitation of our study was that it
was a single-center study including relatively few cases.
Another limitation was that it was retrospective with data
collected from the patients’ ﬁles.
4. DiscussionIn the United States, intoxications due to antiepileptic
drugs comprise 3% of all intoxications. Among antiepileptic
drug intoxications, most are caused by FGAEs, namely
VPA, carbamazepine, phenytoin, and phenobarbital.
Serum level of carbamazepine
p kk p
0.404a 0.145 0.386a
0.520a 0.602 <0.001a
0.130a −0.568 <0.001a
0.156a −0.365 0.024a
<0.001a
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Intoxications with new generation antiepileptics (such
as lamotrigine, topiramate, felbamate, gabapentin) are
rarely seen, and the data on their toxicity is limited by
case reports [1–3]. In the study including 1028 patients,
Bonilha et al. had showed that the most frequent cause
of antiepileptic intoxication is phenobarbital, that is the
drug of poisoning in 250 patients [4]. In another study
including 652 patients, Nixon et al. had reported that
carbamazepine is the leading cause of poisoning, that is
the drug of poisoning in 306 patients [5]. In our study,
we found that carbamazepine is the most frequent cause
of antiepileptic poisoning. Bonilha et al. [4] found that
antiepileptic poisoning was most frequently seen in the
25–29 age group. Nixon et al. [5] found that antiepileptic
poisoning was most frequently seen in the 30–39 age
group, whereas we found that it was most frequently seen
in the 18–20 age group with a rate of 46.3%.
The serum lactate levels patients poisoned by FGAEs
on admission to emergency department were signiﬁcantly
higher than the levels of patients poisoned by SGAEs.
Accordingly FGAEs are metabolically more toxic than
SGAEs.
In 2002, The American Association of Poison Control
Centers has reported 5645 cases of intoxication caused
by carbamazepine, which was the most frequent cause
of intoxication in our study [6]. The main symptoms of
carbamazepine poisoning are ataxia, nystagmus, ophthal-
moplegia, dystonia, mydriasis, and sinus tachycardia. In
severe intoxications, myoclonus, seizures, hyperthermia,
coma, arrhythmias, and respiratory depression may  also
be observed. Due to having a structure similar to tricyclic
antidepressants, carbamazepine may  cause QRS and QT
interval prolongation. The mortality rate, which is gener-
ally due to cardiovascular toxicity, is about 2% [1]. In our
study, there was no mortality caused by carbamazepine
intoxication.
Although the correlation between the serum carba-
mazepine level and the clinical ﬁndings is weak, severe
intoxication occurs at carbamapezine levels of >20 mg/L.
Cardiovascular toxicity may  occur at serum carbamazepine
levels of >40 mg/L and death may  occur at 120 mg/L [7]. In
our study, the minimum, maximum, and average serum
levels of carbamapezine were 5.2 mg/L, 69.6 mg/L, and
24.4 mg/L, respectively. There were serious intoxication
ﬁndings, particularly in Groups 2 and 3. (Group 2: serum
carbamazepine levels from 15 to 30 mg/L, the Group 3:
30 mg/L is above.)
The main therapeutic approach to carbamazepine
intoxication is supportive therapy. In order to eliminate
the drug, recurrent doses of activated charcoal are given,
and charcoal hemoperfusion is carried out. High-ﬂow
hemodialysis is also an effective method of therapy. Fur-
thermore, plasmapheresis was found to be effective both
in reducing serum levels of carbamazepine and in clini-
cal improvement [8]. Sodium bicarbonate is recommended
in cases with QRS interval of >10 s [1]. In our study, out
of 38 cases with carbamazepine intoxication, 15 received
hemoperfusion and 2 patients received sodium bicarbon-
ate treatment.
Some authors have reported that there is a correla-
tion between the serum carbamazepine level and theReports 2 (2015) 56–62
neurological symptoms, and that the frequencies of
seizures and coma increase at serum carbamazepine
levels of 20–40 mg/L [9–12]. In his study on 82 cases of
carbamazepine intoxication, Tibbals [13] has reported
that serum carbamazepine level is correlated with coma,
confusion, severity or depth of hypotension, and the need
for mechanical ventilation. He has also reported deaths
due to cardiac insufﬁciency, aspiration pneumonia, and
septicemia in carbamazepine intoxication [13]. Brahmi
et al. [14] have found a signiﬁcant negative correlation
between the serum carbamazepine level and GCS score
(r = −0.58; p = 0.01). In our study, we  also determined a
signiﬁcant negative correlation between carbamazepine
and GCS score. We  also observed a closer association with
GCS score and a higher incidence of central nervous system
depression ﬁndings when carbamazepine levels were over
15 mg/L. Ciszowski et al. [15] have reported a positive cor-
relation (r = 0.68; p < 0.001) between the carbamazepine
level and the systolic and diastolic blood pressure. In our
study, we  saw no association or correlation between the
serum carbamazepine level and the systolic blood pressure.
As far as we know, there is no study in the litera-
ture demonstrating the positive correlation between the
serum carbamazepine level and the serum lactate level. In
our study, we  determined a signiﬁcant positive correlation
between the serum carbamazepine level and the serum lac-
tate level. Furthermore, we observed a closer association
between the serum carbamazepine levels of over 15 mg/L
and the serum lactate level. These data indicate that the
serum lactate level can be used as a prognostic biomarker
in carbamazepine intoxications.
In the year 2000, The American Association of Poi-
son Control Centers has reported over 5000 cases of
intoxication caused by VPA, which was the second most
frequent cause of intoxication in our study [16]. The
most frequent ﬁndings in VPA intoxication are coma
and central nervous system depression, which can lead
to respiratory depression. Tachycardia and hypoten-
sion are rare in VPA poisoning. Pupillary miosis may
occur, mimicking opiate poisoning. Moreover, pancreatitis,
hyperammonemia, metabolic and hematological disorders,
and cardiopulmonary arrest can occur. In cases with severe
VPA poisoning, optic nerve atrophy, brain edema, non-
cardiogenic pulmonary edema, anuria, and pancreatitis can
be observed as late sequelae [7].
Although there is a weak correlation between the serum
VPA level and the clinical ﬁndings, numbness can be
observed in patients with serum VPA level of >500 mg/L,
and in patients with serum VPA levels of >1000 mg/L,
metabolic disorders and coma may  be seen [7]. In our study,
the minimum, maximum, and average levels of serum VPA
were 65 mg/L, 1005 mg/L, and 164.3 mg/L, respectively. We
observed severe intoxication symptoms, particularly in
Group 3. (Group 3: VPA serum level of 125 mg/L above.)
The main treatment modality in antiepileptic poison-
ing is supportive therapy. Naloxone is recommended for
some patients who  show symptoms of central nervous
system depression [17]. Seizure cases can be treated with
intravenous diazepam with a dosage of 0.1–0.3 mg/kg [18].
To decrease the serum drug level, extracorperal meth-
ods such as hemoﬁltration and also carnitine are used
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7,17–20]. In patients with VPA intoxication, hemoﬁltra-
ion or hemoperfusion should be considered in cases of
enal insufﬁciency, severe metabolic disorders, continu-
us disorder of consciousness and seizures, and refractory
ypotension [21,22]. Also Spiller et al. [23] suggested
hat hemoperfusion or hemoﬁltration could be an addi-
ional treatment option in patients with serum VPA levels
850 mg/L. In our study, out of 26 VPA-intoxicated patients,
 patients had undergone hemoperfusion.
Although the number of reported cases of VPA intoxica-
ion is limited, treatment with carnitine is recommended
or such cases to prevent acute hepatic insufﬁciency and
etabolic abnormalities, as well as to correct the disorders
f consciousness [24,25]. The Pediatric Neurology Advi-
ory Committee and some textbooks strongly recommend
arnitine treatment (50–100 mg/kg/day) in case of VPA
verdose and hepatic toxicity [26–28]. However, there is
o strong evidence that carnitine removes the toxicity (evi-
ence level C) [29]. In our study, 7 cases received carnitine
reatment, and there were no side-effects or allergic reac-
ions induced by carnitine.
Although there is no association between the plasma
PA concentrations and the severity of central nervous sys-
em toxicity, oral intake of VPA at a dose of over 200 mg/kg
r plasma concentration of VPA over 180 mg/L lead to
evere central nervous system depression [30,31]. In our
tudy, we did not ﬁnd a signiﬁcant association or a sig-
iﬁcant correlation between GCS score and the VPA level,
ven in the patient group with serum VPA levels of over
25 mg/L.
Since pancreatitis, hyperammoniemia, and metabolic
nd hematological disorders can appear in VPA intoxica-
ions, and since high levels of lactate and ammonia are
ssociated with cerebral edema and disorders of conscious-
ess, we assessed the association between the serum VPA
evel and the serum lactate and ammonia levels [32]. We
bserved no signiﬁcant association between serum VPA
evel and the serum lactate level. However, we found a
tatistically signiﬁcant positive correlation between the
erum VPA level and the ammonia level. However, many
elevant studies have been unable to explain clearly the
ssociation between the serum VPA level and the serum
mmonia level [18,32].
. Conclusion
The ﬁrst generation antiepileptics are more toxic than
he second generation antiepileptics. In patients with car-
amazepine levels, particularly those over 30 mg/L, severe
isorders of consciousness, cardiovascular toxicity, and
etabolic disorders may  be observed. In carbamazepine
ntoxications, the lactate level can be used as a prognostic
iomarker. In VPA intoxications, there is a positive correla-
ion between the serum VPA level and the ammonia level.
n account of this ﬁnding, one should be more careful about
yperammonemic hepatic encephalopathy as the serum
PA level raises. Hemoperfusion is effectively used in the
herapy of carbamazepine and VPA intoxications. In order
o verify the efﬁcacy of carnitine therapy in VPA intoxica-
ions, comprehensive studies with larger number of cases
hould be carried out.
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